全球癌症生物疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

预计癌症生物疗法市场将从 2025 年的 1,461.1 亿美元成长到 2034 年的 2,402.3 亿美元，2026 年至 2034 年的复合年增长率为 5.68%。

随着全球癌症发生率的上升，全球癌症生物疗法市场正在迅速扩张。生物疗法，包括免疫疗法、单株抗体和标靶治疗，正成为重要的治疗选择。这些疗法能够帮助人体免疫系统更有效对抗癌症，其效果优于传统化疗。人们对先进癌症疗法的认识不断提高以及诊断技术的进步，正在推动这个市场的成长。

关键成长要素包括肿瘤学领域的持续研发、政府资助以及创新生物製药临床试验的增加。製药公司正大力投资开发副作用较少的标靶治疗。此外，全球人口老化以及与文明病的癌症病例增加，也提高了对有效治疗方法的需求。同时，个人化医疗的进步正在改善治疗效果，并增强患者的信心。

未来，随着新一代免疫疗法和联合疗法的引入，市场预计将迎来强劲成长。开发中国家医疗基础设施的持续改善将进一步扩大先进癌症治疗的覆盖范围。随着生物技术的进步和监管核准的加快，癌症生物疗法市场有望在全球范围内提供巨大的成长机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球癌症生物疗法市场：依治疗方法类型划分

• 市场分析、洞察与预测
• 单株抗体
• 疫苗
• 细胞激素
• 基因治疗

第五章 全球癌症生物疗法市场：依癌症类型划分

• 市场分析、洞察与预测
• 乳癌
• 肺癌
• 结肠癌
• 摄护腺癌

第六章：全球癌症生物疗法市场：依给药途径划分

• 市场分析、洞察与预测
• 静脉注射
• 皮下注射
• 口服
• 肌肉内注射

第七章 全球癌症生物疗法市场：以最终用户划分

• 市场分析、洞察与预测
• 医院
• 癌症研究机构
• 製药公司

第八章 全球癌症生物疗法市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Bristol-Myers Squibb
  • Sanofi
  • Eli Lilly
  • Regeneron Pharmaceuticals
  • Celgene
  • AbbVie
  • Gilead Sciences
  • Amgen
  • Intuitive Surgical
  • Johnson And Johnson
  • Pfizer
  • Merck
  • Roche
  • AstraZeneca
  • Novartis

The Cancer Biological Therapy Market size is expected to reach USD 240.23 Billion in 2034 from USD 146.11 Billion (2025) growing at a CAGR of 5.68% during 2026-2034.

The Global Cancer Biological Therapy Market is expanding rapidly due to the increasing prevalence of cancer worldwide. Biological therapies, including immunotherapy, monoclonal antibodies, and targeted therapies, are becoming key treatment options. These therapies help the body's immune system fight cancer more effectively compared to traditional chemotherapy. Rising awareness about advanced cancer treatments and improved diagnostic technologies are driving the growth of this market.

Key growth drivers include continuous research and development in oncology, government funding, and growing clinical trials for innovative biologic drugs. Pharmaceutical companies are investing heavily in developing targeted therapies with fewer side effects. The aging global population and lifestyle-related cancer cases are also increasing demand for effective treatment options. Additionally, advancements in personalized medicine are improving treatment outcomes and boosting patient confidence.

In the future, the market is expected to witness strong growth with the introduction of next-generation immunotherapies and combination treatment approaches. Expanding healthcare infrastructure in developing countries will further increase accessibility to advanced cancer treatments. As biotechnology continues to evolve and regulatory approvals become faster, the cancer biological therapy market is likely to offer significant growth opportunities worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Therapy

• Monoclonal Antibodies
• Vaccines
• Cytokines
• Gene Therapy

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

By Administration Route

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By End User

• Hospitals
• Cancer Research Institutes
• Pharmaceutical Companies

COMPANIES PROFILED

• BristolMyers Squibb, Sanofi, Eli Lilly, Regeneron Pharmaceuticals, Celgene, AbbVie, Gilead Sciences, Amgen, Intuitive Surgical, Johnson and Johnson, Pfizer, Merck, Roche, AstraZeneca, Novartis
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY TYPE OF THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Therapy
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cytokines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Administration Route
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type Of Therapy
  • 8.2.2 By Cancer Type
  • 8.2.3 By Administration Route
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type Of Therapy
  • 8.3.2 By Cancer Type
  • 8.3.3 By Administration Route
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type Of Therapy
  • 8.4.2 By Cancer Type
  • 8.4.3 By Administration Route
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type Of Therapy
  • 8.5.2 By Cancer Type
  • 8.5.3 By Administration Route
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type Of Therapy
  • 8.6.2 By Cancer Type
  • 8.6.3 By Administration Route
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CANCER BIOLOGICAL THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bristol-Myers Squibb
  • 10.2.2 Sanofi
  • 10.2.3 Eli Lilly
  • 10.2.4 Regeneron Pharmaceuticals
  • 10.2.5 Celgene
  • 10.2.6 AbbVie
  • 10.2.7 Gilead Sciences
  • 10.2.8 Amgen
  • 10.2.9 Intuitive Surgical
  • 10.2.10 Johnson And Johnson
  • 10.2.11 Pfizer
  • 10.2.12 Merck
  • 10.2.13 Roche
  • 10.2.14 AstraZeneca
  • 10.2.15 Novartis